Canaccord analyst Edward Nash downgraded Morphic (MORF) to Hold from Buy with a price target of $57, down from $66, after the company agreed to be acquired by Eli Lilly (LLY) for a purchase price of $57 per share in cash.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MORF: